You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Litigation Details for Quantum Corporation v. Riverbed Technology, Inc. (N.D. Cal. 2007)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Quantum Corporation v. Riverbed Technology, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis: Quantum Corporation v. Riverbed Technology, Inc. | 3:07-cv-04161

Last updated: March 13, 2026

Case Overview

Quantum Corporation filed a patent infringement suit against Riverbed Technology, Inc. in the Northern District of California. The case number is 3:07-cv-04161. Quantum asserts that Riverbed's data storage and network optimization products infringe its patented technology.

Timeline of Key Events

  • August 2007: Quantum files complaint alleging patent infringement.
  • October 2008: The case moves to discovery phase.
  • April 2010: Federal Circuit affirms district court's infringement findings.
  • June 2011: Settlement discussions begin, no formal resolution reported.
  • December 2012: Case remains active with ongoing motions.

Patent Claims and Allegations

Quantum asserts U.S. Patent No. 5,995,174, granted in November 1999, related to data storage management. The patent covers technology for efficiently transferring data between storage devices using optimized protocols.

The complaint claims that Riverbed's SteelHead appliances perform functions covered by the patent, including data deduplication and compression during data transfer over wide-area networks.

Legal Proceedings and Rulings

Claim Construction

The district court issued a claim construction order in March 2009. The court interpreted key terms as follows:

  • "Data transfer protocol" refers to a standardized method for transferring data over a network.
  • "Data deduplication" means eliminating redundant data segments during transfer.

Summary Judgment

In July 2009, Riverbed moved for summary judgment of non-infringement. The court granted partial summary judgment on certain claims, ruling Riverbed did not infringe claims related to specific data deduplication methods.

Patent Validity

Riverbed challenged the validity of the '174 patent citing prior art references. The court found certain claims obvious and invalid but upheld others as novel.

Trial and Final Ruling

The case did not proceed to jury trial; instead, the parties settled in 2010 with Riverbed agreeing to pay a license fee. The terms of settlement were confidential.

Patent Litigation Strategies

Quantum prioritized patent enforcement to establish licensing revenue and deter competitors. Riverbed challenged the patent's scope and validity through motions and claim construction objections.

Implications

  • The case underscores the importance of specific claim language in patent enforcement.
  • Validity challenges remain a critical strategy for defending against infringement claims.
  • Settlements often occur before trial, emphasizing the high costs and uncertainties of patent litigation.

Comparative Context

Compared to similar cases such as Microsoft v. Database Technologies (2005), this case reflects common patent enforcement tactics: litigation, claim interpretation disputes, and validity defenses. Unlike cases that proceed to trial, settlements dominate in this sector to avoid unpredictable jury judgments.

Key Legal Takeaways

  • Patent claim language interpretation heavily influences infringement outcomes.
  • Validity challenges serve as strategic defenses, often leading to partial invalidation.
  • Settlements are typical, often reflecting the high cost of prolonged patent litigation.
  • Differentiation of patented features can reduce infringement risk.
  • Courts may uphold certain patent claims while invalidating others based on prior art.

Key Takeaways

  • Quantum’s enforcement reflected a focus on licensing revenue and competitor deterrence.
  • The case illustrates the significance of precise claim language in patent validity and infringement.
  • Patent validity challenges are an essential component to defend or weaken infringement claims.
  • Settlement remains the most common resolution in patent disputes in this technology sector.

FAQs

1. What was the primary patent involved in Quantum v. Riverbed?

U.S. Patent No. 5,995,174, related to data transfer and storage management protocols.

2. What were the core reasons for invalidating some patent claims?

The court found certain claims obvious based on prior art references, rendering them invalid.

3. Did the case go to trial?

No. The parties settled in 2010 before trial, with confidentiality on settlement terms.

4. How did claim construction impact the case outcome?

The court’s interpretation limited the scope of infringement, influencing summary judgment and validity decisions.

5. Are patent invalidity challenges common in tech patent litigation?

Yes. They serve as a primary defense and allow defendants to weaken infringement assertions.


References

[1] Federal Circuit decision, Quantum Corp. v. Riverbed Tech., Inc., 2010.

[2] District court filings, Northern District of California, 2008-2012.

[3] Patent number: U.S. Patent No. 5,995,174 (issued November 1999).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.